The combination of anti-PD-1 therapy Keytruda with tyrosine kinase inhibitor Inlyta (axitinib) reduced risk of death in RCC by around 47%, compared with Pfizer’s established cancer drug Sutent ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday? Why Is Teva Stock Trading Higher On Tuesday? Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday? Why Is Teva Stock ...